Amgen, Pfizer, and Celltrion are key players poised for rapid expansion in the biosimilars market in the US.
1 report, 1 independent
Updated Jul 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amgen, Pfizer, and Celltrion are key players poised for rapid expansion in the biosimilars market in the US.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Regulatory settlements and investment targets are driving biosimilar launches and facility expansion in the US.Sub-event
Amgen, Pfizer, and Celltrion are key players poised for rapid expansion in the biosimilars market in the US.1 source
Keep exploring
The entities involved
-
Amgen
American multinational biopharmaceutical company
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Celltrion
South Korean biopharmaceutical company
Nothing else this week.
Related events
- Major pharmaceutical companies are competing for investment capital.
- AbbVie, Amgen, Micron Technology, and NetApp all showed strength in the stock market on October 7, 2026.
- Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
- BioNTech announced new partnerships with Genmab, Pfizer, Bristol-Myers Squibb, and Genentech.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
Coverage
Newest first; wire copies grouped- GlobeNewswireBiosimilars Markets Global Forecast Report 2025-2035 | Launch of Glp-1 Biosimilars, Increasing Strategic Partnerships and Collaborations, & Growing Focus on Advanced R&D Fueling Opportunities The glo